These results indicate that inhibition of AhR-PD-L1 axis and inhibition of AhR in immune cells pave the way to anti-lung cancer efficacy of AhR inhibitor, and the ANF/anti-PD-L1 antibody combination represents a novel strategy of cancer immunotherapy. This evidence concerns the gene AHR and lung cancer.